The burden of hepatitis C in Europe from the patients’ perspective: a survey in 5 countries

BMC Gastroenterology

Table 4 Health outcomes in treatment-naïve HCV patients and matched controls

	HCV never treated		Matched controls		p-value
	(n = 139)		(n = 139)
	M	SD	M	SD
Work productivity & activity impairment
Absenteeism	6.67%	18.26%	2.84%	13.36%	.157
Presenteeism	24.84%	30.07%	12.86%	21.28%	.006
Overall work impairment	28.65%	32.94%	14.75%	24.57%	.004
Activity impairment	31.73%	30.57%	29.28%	31.48%	.374
Healthcare resource utilization
Physician visits	19.54	24.62	12.06	16.80	.001
ER visits	0.46	1.90	0.35	1.15	.986
Hospitalizations	0.36	1.16	0.19	0.99	.120
Quality of life (SF-12v2)
MCS	44.72	10.43	45.93	11.64	.361
PCS	43.49	10.26	45.99	10.72	.048
Health utility	0.68	0.13	0.71	0.15	.080

Comparisons of work productivity impairment are based on 65 treatment-naïve HCV patients and 65 matched controls. All other comparisons include the entire samples.

ISSN: 1471-230X